The treatment of Drug Resistant TB involved the use of long regimens with poor efficacy and a high drug related adverse event rate. Internationally, a successful outcome of treatment of who are diagnosed DR TB was 50%. Many patients started on treatment are loss to the program in part due to the side effects. In addition, there is increasing evidence of that transmission of DR TB is occurring in the community. While standardised regimens are used when DR TB is diagnosed, the evidence base for is of poor quality and based largely on cohort data. However in the last few years there have been major advances. The World Health Organisation issued guideline in May 2016 that included the use of a shortened course for the treatment of MDR. This session will discuss the rationale and some of the challenges in implementing this new recommendation. In addition, there have been a number of new and repurposed drugs have been introduced into the treatment of DR TB. Some of the research into the use of these drugs will be presented as well as the outcomes of their use in National TB programs.